Publications
Detailed Information
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cortes, J. | - |
dc.contributor.author | Baselga, J. | - |
dc.contributor.author | Im, Y. -H. | - |
dc.contributor.author | Im, S. -A. | - |
dc.contributor.author | Pivot, X. | - |
dc.contributor.author | Ross, G. | - |
dc.contributor.author | Clark, E. | - |
dc.contributor.author | Knott, A. | - |
dc.contributor.author | Swain, S. M. | - |
dc.date.accessioned | 2022-03-22T09:11:31Z | - |
dc.date.available | 2022-03-22T09:11:31Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.created | 2021-05-11 | - |
dc.date.created | 2021-05-11 | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2013-10 | - |
dc.identifier.citation | Annals of Oncology, Vol.24 No.10, pp.2630-2635 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | 130935 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177233 | - |
dc.description.abstract | The phase III CLEOPATRA study demonstrated that combining pertuzumab with trastuzumab plus docetaxel significantly improves progression-free and overall survival in previously untreated HER2-positive metastatic breast cancer. Here, we report health-related quality-of-life (HRQoL) results from CLEOPATRA. Participants were randomly assigned to pertuzumab or placebo, each given with trastuzumab plus docetaxel every 3 weeks. Pertuzumab and trastuzumab were administered until progression and six or more docetaxel cycles were recommended. Time from randomization to a >= 5-point decrease in Trial Outcome Index-Physical/Functional/Breast (TOI-PFB) of the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire was analyzed as a prespecified secondary end point. A post hoc exploratory analysis investigated time to >= 2-point deterioration in Breast Cancer Subscale (BCS) score. Time to >= 5-point decline in TOI-PFB did not differ significantly between the pertuzumab and placebo arms [hazard ratio (HR), 0.97; P = 0.7161]. The median times to TOI-PFB deterioration were 18.4 and 18.3 weeks, respectively (approximately six cycles). The mean TOI-PFB declined slightly until week 18 and recovered thereafter. Pertuzumab increased time until BCS deterioration versus placebo (median 26.7 versus 18.3 weeks; HR, 0.77; P = 0.0061). Combining pertuzumab with trastuzumab and docetaxel had no adverse impact on HRQoL and may prolong time to worsening of breast cancer-specific symptoms. | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1093/annonc/mdt274 | - |
dc.citation.journaltitle | Annals of Oncology | - |
dc.identifier.wosid | 000325153800028 | - |
dc.identifier.scopusid | 2-s2.0-84884644183 | - |
dc.citation.endpage | 2635 | - |
dc.citation.number | 10 | - |
dc.citation.startpage | 2630 | - |
dc.citation.volume | 24 | - |
dc.identifier.sci | 000325153800028 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, S. -A. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | RANDOMIZED CLINICAL-TRIALS | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | PLUS TRASTUZUMAB | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | LAPATINIB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | WOMEN | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordAuthor | docetaxel | - |
dc.subject.keywordAuthor | health-related quality-of-life | - |
dc.subject.keywordAuthor | metastatic breast cancer | - |
dc.subject.keywordAuthor | pertuzumab | - |
dc.subject.keywordAuthor | trastuzumab | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.